Experimental HIV Drugs
Experimental HIV Drugs
ICAAC 2012: New Long-acting HIV Fusion Inhibitor Albuvirtide Looks Promising in Early Studies
- Details
- Category: HIV Treatment
- Published on Tuesday, 11 September 2012 00:00
- Written by Liz Highleyman
A new fusion inhibitor that prevents HIV entry into cells showed potent antiviral activity in early clinical studies and has a long half-life suggesting it may be suitable for once-weekly dosing, Chinese researchers reported yesterday at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) in San Francisco. 
Coverage of the 2012 Interscience Conference on Antimicrobial Agents and Chemotherapy
- Details
- Category: HIV Treatment
- Published on Tuesday, 11 September 2012 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, September 9-12, 2012.
Topics highlighted this year include experimental antiretroviral drugs, complications related to HIV and its treatment, recent developments in hepatitis C therapy, cancer caused by HPV, influenza, tuberculosis, and STDs.
HIVandHepatitis.com ICAAC 2012 conference section
HIV Attachment Inhibitor BMS-663068 Looks Good in Early Studies
- Details
- Category: HIV Treatment
- Published on Tuesday, 04 September 2012 00:00
- Written by Liz Highleyman
Bristol-Myers Squibb's novel attachment inhibitor pro-drug BMS-663068, which binds to HIV's gp120 envelope protein, potently suppressed viral load and was generally well-tolerated in a week-long monotherapy study, according to a report in the August 14, 2012, advance online edition of the Journal of Infectious Diseases. A related study showed that the active form of the drug worked against virus resistant to other entry inhibitors. 
Coverage of 2012 Interscience Conference on Antimicrobial Agents and Chemotherapy
- Details
- Category: HIV Treatment
- Published on Tuesday, 11 September 2012 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy -- better known as ICAAC -- in San Francisco, September 9-12, 2012.
Topics highlighted this year include experimental antiretroviral drugs, complications related to HIV and its treatment, recent developments in hepatitis C therapy, and cancer caused by HPV, along with a gamut of other infectious diseases including influenza, tuberculosis, and STDs.
HIVandHepatitis.com ICAAC 2012 conference section
9/11/12
FDA Approves Stribild, Gilead's 4-in-1 Quad Pill for First-line HIV Treatment
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 28 August 2012 00:00
- Written by Liz Highleyman
On August 27, 2012, the U.S. Food and Drug Administration (FDA) approved Stribild, a new single-tablet regimen containing the next-generation integrase inhibitor elvitegravir, the novel boosting agent cobicistat, and tenofovir/emtricitabine (the drugs in Truvada). Stribild is indicated for HIV positive adults starting treatment for the first time.
More Articles...
- AIDS 2012: Quad Matches Atripla and Atazanavir Regardless of Viral Load or CD4 Count
- AIDS 2012: Long-acting HIV Integrase Inhibitor S/GSK1265744 May Allow Monthly Dosing
- AIDS 2012: Once-daily Elvitegravir Suppresses HIV as well as Raltegravir at 96 weeks
- AIDS 2012: Cobicistat Matches Ritonavir as Booster for Atazanavir
Web Design and Development by